Breast Cancer

In patients with HER2+ breast cancer, those who achieved a pathologic complete response following HER2-directed (trastuzumab and/or pertuzumab) neoadjuvant therapy had an increased event-free survival probability compared with patients with residual disease. Read More ›

In the largest retrospective analysis of US patients with ER+/HER2+ nonmetastatic breast cancer, there was no overall survival benefit of treating patients with hormone therapy + trastuzumab compared with hormone therapy alone, and patients treated without chemotherapy had a significantly worse overall survival. Read More ›

IL6ST levels can differentiate ER+/HER2+ patients with breast cancer who respond well to endocrine therapy alone versus those with a poor clinical response who have a higher risk of recurrence, suggesting that there is a potential role for IL6ST in selecting ER+/HER2+ patients who require and benefit from HER2-targeted therapies. Read More ›

All-cause healthcare utilization and costs among patients with metastatic breast cancer were highest for pharmacy costs and for those with metastasis to the central nervous system. Read More ›

The clinical trial design was presented of a phase 1b study to assess the efficacy and tolerability of nivolumab plus stereotactic radiosurgery for patients with breast cancer and brain metastases. Read More ›

The study design is described of an ongoing phase 2 clinical study of tucatinib plus trastuzumab and capecitabine in patients with advanced HER2+ breast cancer and newly diagnosed leptomeningeal metastatic disease. Read More ›

The combination of letrozole, everolimus, and trastuzumab is well tolerated with encouraging clinical activity in heavily pretreated patients with HER2-amplified or mutant advanced breast cancer. Read More ›

The clinical trial design was presented of a single-center, phase 2 study of GDC-0084, a brain-penetrant inhibitor of class I PI3K and mTOR, to evaluate the efficacy of GDC-0084 plus trastuzumab for the treatment of central nervous system metastases in patients with HER2+ breast cancer. Read More ›

Results from the FeDeriCa study showed that a novel subcutaneous fixed-dose formulation of pertuzumab + trastuzumab demonstrated pharmacokinetics, efficacy, and safety comparable to intravenous pertuzumab + trastuzumab (each + chemotherapy) in patients with HER2+ breast cancer. Read More ›

Real-world practice patterns regarding the use of trastuzumab emtansine as adjuvant therapy in HER2+ early breast cancer were significantly changed after presentation and publication of the results from the phase 3 KATHERINE study. Read More ›

Page 1 of 8

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: